Here are 1-3 brief analogies for BridgeBio Pharma (BBIO):

• The Vertex Pharmaceuticals for a broader spectrum of genetic diseases.

• Like a smaller, more focused Amgen, exclusively developing drugs for genetic diseases and cancers with clear genetic drivers.

• Acoramidis (AG10): An investigational therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and fatal heart disease.
• BBP-870: An investigational therapy for achondroplasia, the most common form of skeletal dysplasia leading to dwarfism.
• BBP-418: An investigational therapy for limb-girdle muscular dystrophy type 2i (LGMD2i), a rare and progressively debilitating genetic muscle disease.
• BBP-631: An investigational gene therapy for congenital adrenal hyperplasia (CAH), a genetic disorder affecting the adrenal glands.

BridgeBio Pharma (BBIO) is primarily a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing medicines for genetic diseases and cancers with clear genetic drivers. As such, it currently has limited commercial product sales.

According to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, BridgeBio Pharma explicitly states:

"We currently have limited product sales from our approved products and therefore do not have any major customers from which we derive a substantial portion of our revenue."

While BridgeBio has a few approved products, such as Olpruva™ (ACER-001) for urea cycle disorders (UCDs) in the U.S. (approved December 2023), NULIBRY® (palovarotene) for fibrodysplasia ossificans progressiva (FOP) in Europe, Canada, and Australia, and AGAMREE® (vildopaf) for achondroplasia in Europe, these products are in the early stages of commercialization or are marketed through partners. Their product sales revenue for 2023 was only $1.0 million.

Pharmaceutical companies selling prescription drugs typically do so through a distribution network rather than directly to individuals. This network usually includes:

1. Pharmaceutical wholesalers and distributors.
2. Specialty pharmacies.
3. Hospitals and healthcare systems.

However, given BridgeBio's current stage and explicit statement in their SEC filing, no single company or category of companies constitutes a "major customer" for BridgeBio Pharma at this time.

• Fujifilm Holdings Corporation (FUJIY)
• Ultragenyx Pharmaceutical Inc. (RARE)

Neil Kumar, PhD, Chief Executive Officer and Director

Neil Kumar is the CEO and Founder of BridgeBio Pharma, Inc., established in 2015 to develop medicines for genetic diseases. He also served as the Chief Executive Officer of BridgeBio’s subsidiary, Eidos Therapeutics, Inc.. Before founding BridgeBio, Dr. Kumar was a Principal at Third Rock Ventures, where he focused on new company formation and managed portfolio companies, and served as the interim Vice President of Business Development and Operations for MyoKardia. Earlier in his career, he was an Associate Principal at McKinsey & Company, developing strategies for pharmaceutical and medical device companies. He is also a founder and sits on the board of BridgeBio Oncology Therapeutics, and is Founder and Executive Chair of GondolaBio.

Thomas Trimarchi, PhD, President and Chief Financial Officer

Thomas Trimarchi was appointed President and Chief Financial Officer of BridgeBio Pharma in March 2025. He previously held the role of Principal Financial Officer and is responsible for leading the company's financial planning and analysis (FP&A) and accounting operations. Dr. Trimarchi joined BridgeBio in 2018 as Chief Product Officer.

Charles Homcy, MD, Co-Founder, Chairman of Pharmaceuticals, Lead Director

Dr. Charles Homcy is the Co-Founder, Chairman of Pharmaceuticals, and Lead Director at BridgeBio Pharma, Inc..

Richard Scheller, PhD, Chairman of Research & Development and Director

Dr. Richard Scheller serves as the Chairman of Research & Development and a Director at BridgeBio Pharma, Inc..

Uma Sinha, PhD, Chief Scientific Officer

Uma Sinha is the Chief Scientific Officer at BridgeBio Pharma, Inc..

The clear emerging threat to BridgeBio Pharma (BBIO) is the rapid advancement of gene-editing therapies targeting transthyretin (ATTR) amyloidosis, the same disease indication for which BridgeBio's lead product candidate, acoramidis, is being developed.

Companies like Intellia Therapeutics (e.g., NTLA-2001) are developing single-dose, in vivo gene-editing treatments designed to permanently silence the TTR gene, which produces the misfolded protein responsible for ATTR amyloidosis. While acoramidis is an oral small molecule designed for chronic stabilization of the TTR protein, gene-editing therapies offer the potential for a one-time functional cure or long-term disease modification by stopping TTR production at its source. If these gene-editing treatments demonstrate long-term safety and efficacy in ongoing and future clinical trials, they could fundamentally disrupt the treatment landscape for ATTR amyloidosis, potentially limiting the market potential and competitive advantage of chronically administered therapies like acoramidis, even if acoramidis secures regulatory approval.

BridgeBio Pharma's main products and their addressable markets are as follows:

• Attruby (acoramidis) for Transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM): The ATTR-CM market was estimated at $1.7 billion in 2023 and is referred to as a $3 billion market globally. Annual total revenue for Acoramidis hydrochloride is projected to reach $1.18 billion by 2033 in the U.S.. BridgeBio aims to achieve more than 30% market share for Attruby. The drug is approved in the U.S. and has marketing authorization from the European Commission, with plans to expand into additional markets beyond the U.S., EU, and Japan.
• Low-dose infigratinib for Achondroplasia: The market for achondroplasia is estimated at over $1 billion (global). BridgeBio anticipates that infigratinib, if approved, could capture a significant market share.
• Encaleret for Autosomal Dominant Hypocalcemia type 1 (ADH1): The market for ADH1 is estimated at over $1 billion (global). There are approximately 25,000 estimated carriers of gain-of-function variants of the CaSR, the underlying cause of ADH1, in the U.S. and EU. The revenue for Encaleret is expected to reach an annual total of $206 million by 2035 in the U.S..
• BBP-418 for Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMD2I/R9): The market for LGMD2I is estimated at over $1 billion (global). The potentially addressable patient population for BBP-418 is 7,000 LGMD2I patients in the U.S. and EU.
• BBP-631 for Congenital Adrenal Hyperplasia (CAH): BridgeBio has discontinued the development of BBP-631 for CAH, as the Phase 1/2 trial results did not meet the target for "transformational results". While the global congenital adrenal hyperplasia market is projected to grow from $0.518 billion in 2024 to $1.055 billion by 2035, and there were prior revenue expectations for BBP-631 of $162 million globally by 2038, BridgeBio is no longer pursuing its development for this indication.

1. Continued Commercial Growth of Attruby (acoramidis): Attruby, approved in the U.S., EU, Japan, and UK in November 2024 for transthyretin amyloid cardiomyopathy (ATTR-CM), has demonstrated a strong launch with sales significantly surpassing initial estimates. The drug's strong market reception, competitive pricing, and differentiated clinical profile are expected to drive continued growth through increasing adoption by physicians and expansion within the ATTR-CM market. As of Q3 2025, Attruby accounted for 89.6% of BridgeBio's total revenue, with sales reaching $108.1 million. Analysts project Attruby's peak sales to reach approximately $2.6 billion.
2. Potential Launch of BBP-418 for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9): BridgeBio reported positive topline results for BBP-418's Phase 3 FORTIFY trial, which demonstrated statistically significant improvements in functional measures for patients with LGMD2I/R9. The company aims to submit a New Drug Application (NDA) for this program by mid-2026. If approved, BBP-418 would be the first approved therapy for individuals living with this rare genetic disorder.
3. Potential Launch of Encaleret for Autosomal Dominant Hypocalcemia Type 1 (ADH1): Positive topline results have been reported from the Phase 3 CALIBRATE study for encaleret in ADH1, with a high percentage of participants achieving target calcium ranges. BridgeBio anticipates submitting an NDA for encaleret by mid-2026. This drug has the potential to be the first approved therapy for individuals with ADH1.
4. Potential Launch of Infigratinib for Achondroplasia: Topline data from the Phase 3 PROPEL 3 study of infigratinib for children with achondroplasia is expected in early 2026. This candidate has been highlighted for its potential to achieve peak sales exceeding $2 billion and would represent the first approved oral therapy for this condition. BridgeBio has also reached regulatory alignment with the FDA for clinical development in infants and expects to initiate studies by year-end.

Share Repurchases

• In May 2021, BridgeBio Pharma announced a share repurchase program authorizing the company to repurchase up to $150 million worth of its outstanding common stock.
• In February 2025, the company intended to use up to $50 million of the net proceeds from a convertible senior notes offering to repurchase shares of its common stock.
• During the first quarter of 2025, BridgeBio repurchased $48.3 million of common stock using proceeds from the 2031 Notes.

Share Issuance

• In March 2023, BridgeBio commenced an underwritten public offering of $150 million in common stock, with an option for underwriters to purchase an additional $22.5 million.
• In September 2023, BridgeBio completed a private investment in public equity (PIPE) financing, issuing and selling common stock for approximately $250 million, led by Qatar Investment Authority (QIA).
• In March 2024, the company priced an underwritten public offering of 8,620,690 shares of common stock at $29.00 per share, expecting gross proceeds of approximately $250.0 million.

Inbound Investments

• In September 2023, BridgeBio completed a $250 million private investment in public equity (PIPE) financing, with Qatar Investment Authority (QIA) as the lead investor.
• In January 2024, BridgeBio secured up to $1.25 billion in strategic financing from Blue Owl Capital and Canada Pension Plan Investment Board (CPP Investments) through a combination of senior secured debt and royalty investment.
• In June 2025, the company received a $300 million upfront payment from HealthCare Royalty (HCRx) and Blue Owl Capital through a royalty financing agreement, monetizing 60% of European royalties on the first $500 million of annual BEYONTTRA net sales.

Outbound Investments

• In January 2021, BridgeBio completed its acquisition of all outstanding shares of Eidos Therapeutics Inc. that it did not already own, with an aggregate transaction value of approximately $1.03 billion for the remaining 36.35% of shares.
• In July 2020, BridgeBio established a strategic partnership with LianBio to expand into China, involving initial payments of $26.5 million and potential future milestone payments of up to $505 million.
• In May 2024, BridgeBio announced a $200 million private financing for its former subsidiary, BridgeBio Oncology Therapeutics (BBOT), to accelerate its oncology portfolio.

Capital Expenditures

• BridgeBio Pharma's capital expenditures were reported as $0.46 million for 2024, $2.18 million for 2023, and $2.64 million for 2022.
• For the last 12 months as of November 2025, capital expenditures were -$1.11 million.
• A substantial portion of the company's capital is allocated to research and development (R&D), reflecting its focus on advancing its drug development pipeline.